The use of lead follicle diameter to initiate gonadotropin-releasing hormone antagonist does not affect in vitro fertilization clinical pregnancy, implantation, or live birth rates: a prospective, randomized study.
In this prospective, randomized study, waiting for the lead follicle to reach 14 mm before initiating GnRH antagonist administration effectively prevents an LH surge and ovulation during an IVF cycle. Furthermore, delaying GnRH start until the dominant follicle reaches 14 mm neither impacts the clinical pregnancy, implantation, or live birth rates nor increases the incidence of severe ovarian hyperstimulation syndrome.
Dayal
Molina B
MB
Department of Obstetrics and Gynecology, George Washington Medical Faculty Associates, Fertility and IVF Center, Washington, DC 20037, USA. mdayal@mfa.gwu.edu
Frankfurter
David
D
O'Hern
Candice
C
Peak
Douglas
D
Dubey
Anil
A
Gindoff
Paul R
PR
D000328:Adult; D001723:Birth Rate; D010064:Embryo Implantation; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D007231:Infant, Newborn; D007986:Luteinizing Hormone / Q000378:metabolism; D006080:Ovarian Follicle / Q000033:anatomy & histology*; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control; D010060:Ovulation / Q000187:drug effects; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies; D013997:Time Factors
D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone